Literature DB >> 2195085

Mode-specific effects among three treatments for depression.

S D Imber1, P A Pilkonis, S M Sotsky, I Elkin, J T Watkins, J F Collins, M T Shea, W R Leber, D R Glass.   

Abstract

In the NIMH Treatment of Depression Collaborative Research Program (TDCRP), 250 depressed outpatients were randomly assigned to interpersonal psychotherapy, cognitive-behavioral therapy, imipramine plus clinical management, or pill placebo plus clinical management treatments. Although all treatments demonstrated significant symptom reduction with few differences in general outcomes, an important question concerned possible effects specific to each treatment. The therapies differ in rationale and procedures, suggesting that mode-specific effects may differ among treatments, each of which was precisely specified, applied appropriately, and shown to be discriminable. Outcome measures were selected for presumed sensitivity to the different treatments. Findings provided only scattered and relatively insubstantial support for mode-specific differences. None of the therapies produced consistent effects on measures related to its theoretical origins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195085     DOI: 10.1037//0022-006x.58.3.352

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  30 in total

1.  Change in compensatory skills in cognitive therapy for depression.

Authors:  J P Barber; R J DeRubeis
Journal:  J Psychother Pract Res       Date:  2001

Review 2.  Should general practitioners refer patients with major depression to counsellors? A review of current published evidence. Nottingham Counselling and Antidepressants in Primary Care (CAPC) Study Group.

Authors:  R Churchill; M Dewey; V Gretton; C Duggan; C Chilvers; A Lee
Journal:  Br J Gen Pract       Date:  1999-09       Impact factor: 5.386

3.  Are Improvements in Cognitive Content and Depressive Symptoms Correlates or Mediators during Acute-Phase Cognitive Therapy for Recurrent Major Depressive Disorder?

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  Int J Cogn Ther       Date:  2014-01-09

4.  Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.

Authors:  Boadie W Dunlop; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  J Affect Disord       Date:  2017-12-27       Impact factor: 4.839

5.  A measure of cognitions specific to seasonal depression: Development and validation of the Seasonal Beliefs Questionnaire.

Authors:  Kelly J Rohan; Jonah Meyerhoff; Sheau-Yan Ho; Kathryn A Roecklein; Yael I Nillni; Joel J Hillhouse; Michael J DeSarno; Pamela M Vacek
Journal:  Psychol Assess       Date:  2019-03-28

Review 6.  Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators.

Authors:  Ellen Driessen; Steven D Hollon
Journal:  Psychiatr Clin North Am       Date:  2010-09

7.  Cognitive Change across Cognitive-Behavioral and Light Therapy Treatments for Seasonal Affective Disorder: What Accounts for Clinical Status the Next Winter?

Authors:  Maggie Evans; Kelly J Rohan; Lilya Sitnikov; Jennifer N Mahon; Yael I Nillni; Kathryn Tierney Lindsey; Pamela M Vacek
Journal:  Cognit Ther Res       Date:  2013-12

8.  Evaluation of the unique and specific contributions of dimensions of the triple vulnerability model to the prediction of DSM-IV anxiety and mood disorder constructs.

Authors:  Timothy A Brown; Kristin Naragon-Gainey
Journal:  Behav Ther       Date:  2012-12-08

9.  Therapist-reported alliance: Is it really a predictor of outcome?

Authors:  Sigal Zilcha-Mano; Nili Solomonov; Harold Chui; Kevin S McCarthy; Marna S Barrett; Jacques P Barber
Journal:  J Couns Psychol       Date:  2015-08-31

10.  Measuring Dysfunctional Attitudes in the General Population: The Dysfunctional Attitude Scale (form A) Revised.

Authors:  L Esther de Graaf; Jeffrey Roelofs; Marcus J H Huibers
Journal:  Cognit Ther Res       Date:  2009-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.